CAS Number129-56-6
Synonymsanthra[1,9-cd]pyrazol-6(2H)-one; 1,9-PYRAZOLOANTHRONE; Dibenz[cd,g]indazol-6(2H)-one; 1,6-dihydrodibenzo[cd,g]indazol-6-one; Dibenzo[cd,g]indazol-6(2H)-one; 2H-Dibenzo[CD,G]Indazol-6-One; MFCD00022289; EINECS 204-955-6; SP600125
Molecular FormulaC14H8N2O
Molecular Weight220.23
Purity≥98 (HPLC)%
Density1.5±0.1 g/cm3
Boiling Point489.3±14.0 °C at 760 mmHg
Melting Point281~282℃
Appearanceyellow
EINECS204-955-6
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 129-56-6 |
| Catalog No. | 2A-9020638 |
| Chinese Name | 吡唑蒽酮(SP600125) |
| Synonyms | anthra[1,9-cd]pyrazol-6(2H)-one; 1,9-PYRAZOLOANTHRONE; Dibenz[cd,g]indazol-6(2H)-one; 1,6-dihydrodibenzo[cd,g]indazol-6-one; Dibenzo[cd,g]indazol-6(2H)-one; 2H-Dibenzo[CD,G]Indazol-6-One; MFCD00022289; EINECS 204-955-6; SP600125 |
| Molecular Formula | C14H8N2O |
| Molecular Weight | 220.23 |
| Purity | ≥98 (HPLC) |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 489.3±14.0 °C at 760 mmHg |
| Melting Point | 281~282℃ |
| Appearance | yellow |
| Water Solubility | H2O: insoluble |
| Storage Condition | Warehouse Ventilation Low Temperature Drying |
| Application | SP600125 is a reversible, ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. |
| EINECS | 204-955-6 |
| HTC | 2933990090 |
| PubChem ID | 24278395 |
| MDL Number | MFCD00022289 |
| SMILES | O=C1c2ccccc2-c3n[nH]c4cccc1c34 |
| InChI | 1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16) |
| InChI Key | ACPOUJIDANTYHO-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/20638_1_129_56_6.pdf |
| Bioactivity | SP600125 is a reversible and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> MAPK/ERK Pathway >> JNK Research Areas >> Cancer Target JNK1:40 nM (IC50) JNK2:40 nM (IC50) JNK3:90 nM (IC50) Autophagy In Vitro SP600125 is an ATP-competitive inhibitor of JNK2 with a Ki value of 0.19±0.06 μM. SP600125 inhibits the phosphorylation of c-Jun with IC50 of 5 μM to 10 μM in Jurkat T cells. In CD4+ cells, such as Th0 cells isolated from either human cord or peripheral blood, SP600125 blocks cell activation and differentiation and inhibits the expression of inflammatory genes COX-2, IL-2, IL-10, IFN-γ, and TNF-α, with IC50 of 5 μM to 12 μM[1]. In a mouse beta cells MIN6, SP600125 (20 μM) induces the phosphorylation of p38 MAPK and its downstream CREB-dependent promoter activation[2]. In HCT116 cells, SP600125 (20 μM) blocks the G2 phase to mitosis transition and induces endoreplication. This ability of SP600125 is independent of JNK inhibition, but due to its inhibition of CDK1-cyclin B activation upstream of Aurora A and Polo-like kinase 1[3]. In Vivo Administration of SP600125 at 15 or 30 mg/kg i.v. significantly inhibits TNF-α serum levels, whereas oral administration dose-dependently blocks TNF-α expression with significant inhibition observed at 30 mg/kg per os[1]. SP600125 attenuates LPS-induced ALI in rats in vivo. The expression levels of TNF-α and IL-6 in the BALF in rats in the SP600125 group are significantly decreased[4]. Cell Assay Determination of mRNA half-life is performed essentially, except that CD14+ cells are stimulated with (bacterial) lipopolysaccharide (LPS; 50 ng/mL) for 2 h before addition of actinomycin D (5 μg/mL). SP600125 (25 μM) or vehicle (0.5% DMSO vol/vol) is added immediately following the actinomycin D. Analysis is performed by using real-time reverse transcription (RT)-PCR. Total RNA is extracted with an RNeasy Mini kit. TNF mRNA is measured by real time RT-PCR, using a TNF Taqman probe. All data are normalized by using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. The TNF-α forward primer is 5′-CTGGCCCAGGCAGTCAGAT-3′ and the reverse primer is 5′-TATCTCTCAGCTCCACGCCATT-3′. The Taqman probe sequence is 5′-FAM-CCTGTAGCCCATGTTGTAGCAAACCCTCA-TAMRA-3′[1]. Animal Admin Mice[1] Female CD-1 mice (8-10 weeks of age) are dosed i.v. or per oswith SP600125 in PPCES vehicle (30% PEG-400/20% polypropylene glycol/15% Cremophor EL/5% ethanol/30% saline), final volume of 5 mL/kg, 15 min before i.v. injection with LPS in saline (0.5 mg/kg). At 90 min, a terminal bleed is obtained from the abdominal vena cava, and the serum is recovered. Samples are analyzed for mouse TNF-α by using an ELISA. Rats[4] A total of 40 male Wistar rats are randomly divided into four groups (n=10): the control group, LPS group, normal saline group (NS) and the SP600125 group. Acute lung injury (ALI) is induced via intratracheal injection of LPS. Briefly, the rats are anesthetized with pentobarbital sodium followed by intratracheal injection of 5 mg/kg LPS. The rats are then placed in a vertical position and rotated for 1 min to distribute the LPS in the lungs. Normal saline or SP600125 is administered via intraperitoneal injection (15 mg/kg) 10 min after the LPS injection. References [1]. Bennett BL, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A, 2001, 98(24), 13681-13686. [2]. Vaishnav D, et al. SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway. Biochem Biophys Res Commun, 2003, 307(4), 855-860. [3]. Kim JA, et al. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene, 2010, 29(11), 1702-1716. [4]. Zheng Y, et al. JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation ofclaudin-4. Exp Ther Med. 2014 Jul;8(1):153-158. [5]. Zhang H, et al. SP600125 Suppresses Keap1 Expression and Results in NRF2-mediated Prevention of Diabetic Nephropathy. J Mol Endocrinol. J Mol Endocrinol. 2018 Feb;60(2):145-157. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 489.3±14.0 °C at 760 mmHg Melting Point 281~282℃ Molecular Formula C14H8N2O Molecular Weight 220.226 Flash Point 246.8±26.5 °C Exact Mass 220.063660 PSA 45.75000 LogP 3.18 Vapour Pressure 0.0±1.2 mmHg at 25°C Index of Refraction 1.799 InChIKey ACPOUJIDANTYHO-UHFFFAOYSA-N SMILES O=C1c2ccccc2-c2n[nH]c3cccc1c23 Water Solubility H2O: insoluble |
| Use of | SP600125 is a reversible and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. Properties Name Dibenzo[cd,g]indazol-6(2H)-one Synonym More Synonyms Pyrazolanthrone (SP600125) Biological Activity Description SP600125 is a reversible and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> MAPK/ERK Pathway >> JNK Research Areas >> Cancer JNK1:40 nM (IC50) JNK2:40 nM (IC50) JNK3:90 nM (IC50) Cell Assay Determination of mRNA half-life is performed essentially, except that CD14+ cells are stimulated with (bacterial) lipopolysaccharide (LPS; 50 ng/mL) for 2 h before addition of actinomycin D (5 μg/mL). SP600125 (25 μM) or vehicle (0.5% DMSO vol/vol) is added immediately following the actinomycin D. Analysis is performed by using real-time reverse transcription (RT)-PCR. Total RNA is extracted with an RNeasy Mini kit. TNF mRNA is measured by real time RT-PCR, using a TNF Taqman probe. All data are normalized by using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. The TNF-α forward primer is 5′-CTGGCCCAGGCAGTCAGAT-3′ and the reverse primer is 5′-TATCTCTCAGCTCCACGCCATT-3′. The Taqman probe sequence is 5′-FAM-CCTGTAGCCCATGTTGTAGCAAACCCTCA-TAMRA-3′[1]. References [1]. Bennett BL, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A, 2001, 98(24), 13681-13686. [2]. Vaishnav D, et al. SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway. Biochem Biophys Res Commun, 2003, 307(4), 855-860. [3]. Kim JA, et al. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene, 2010, 29(11), 1702-1716. [4]. Zheng Y, et al. JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation ofclaudin-4. Exp Ther Med. 2014 Jul;8(1):153-158. [5]. Zhang H, et al. SP600125 Suppresses Keap1 Expression and Results in NRF2-mediated Prevention of Diabetic Nephropathy. J Mol Endocrinol. J Mol Endocrinol. 2018 Feb;60(2):145-157. Chemical & Physical Properties Molecular Formula C14H8N2O Exact Mass 220.063660 PSA 45.75000 Index of Refraction 1.799 InChIKey ACPOUJIDANTYHO-UHFFFAOYSA-N Water Solubility H2O: insoluble |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Cyproheptadine | 129-03-3 | 2A-9020626 |
| Vat Yellow 2 | 129-09-9 | 2A-9020628 |
| Merbromin | 129-16-8 | 2A-9020629 |
| Sodium butazolidine | 129-18-0 | 2A-9020631 |
| Ergonovine maleate | 129-51-1 | 2A-9020637 |
| Carbic anhydride | 129-64-6 | 2A-9020639 |
| Buclizine dihydrochloride | 129-74-8 | 2A-9020640 |
| Benz[cd]indol-2(1H)-one | 130-00-7 | 2A-9020642 |
| Sodium 4-amino-1-naphthalenesulfonate | 130-13-2 | 2A-9020643 |
| Sodium 1-naphthalenesulfonate | 130-14-3 | 2A-9020644 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS